Watchlist Price Alert

Fulgent Genetics Inc. (FLGT)

NASDAQ: FLGT · Real-Time Price · USD

19.67

1.11 (5.98%)

At close: May 09, 2025, 3:59 PM

19.76

0.48%

After-hours: May 09, 2025, 05:11 PM EDT

5.98% (1D)

Bid	19.58
Market Cap	598.7M
Revenue (ttm)	292.45M
Net Income (ttm)	-40.78M
EPS (ttm)	-1.33
PE Ratio (ttm)	-14.79
Forward PE	-29.66
Analyst	Hold

Ask	19.79
Volume	306,731
Avg. Volume (20D)	491,391
Open	18.56
Previous Close	18.56
Day's Range	18.61 - 19.67
52-Week Range	14.57 - 25.11
Beta	1.01

About FLGT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol FLGT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for FLGT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Fulgent Genetics has released their quartely earnings on May 2, 2025:

Revenue of $73.46M exceeds estimates by $2.2M, with 13.92% YoY growth.

EPS of 0.04 exceeds estimates by 0.22, with 500.00% YoY growth.

Why Price Moved

1 week ago

+19.07%

Fulgent Genetics shares are trading higher after t... Unlock content with Pro Subscription

News

1 week ago · seekingalpha.com

Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript

1 week ago · zacks.com

Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates

Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.01 per share a year ag...

1 week ago · businesswire.com

Fulgent Reports First Quarter 2025 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...

1 month ago · businesswire.com

Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...

1 month ago · seekingalpha.com

Stock Picks From Seeking Alpha's March 2025 New Analysts

In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT...

1 month ago · seekingalpha.com

Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy

CFO bought 1.5 million worth on March 5th, a Price/Book ratio of 0.43x and a Net Current Assets Value (NCAV) of 0.68x that day. Now it's trading at 0.47x Price/Book Value and 0.72x NCAV, showing a sig...

2 months ago · seekingalpha.com

Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Com...

2 months ago · fool.com

Fulgent Genetics Revenue Tops Estimates

Laboratory services and therapeutic development specialist Fulgent Genetics (FLGT 0.53%) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb. ...

2 months ago · zacks.com

Fulgent Genetics, Inc. (FLGT) Q4 Earnings and Revenues Beat Estimates

Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to earnings of $0.28 per share a yea...

2 months ago · businesswire.com

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results